Phase 2 Completed N=68 Randomized Double-blind Treatment

Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer

Source: ClinicalTrials.gov NCT00213980 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jan 2018

Primary outcomePrimary: Change in Bone Mineral Density (BMD) From Baseline to 1 Year — 0.048; 0.007; 0.014; 0.005 grams per cubic centimeter

Summary

This is a two arm, double-blind randomized study looking at the effect of zoledronate, a bisphosphonate, on the bone mineral density (BMD) of postmenopausal women with breast cancer.

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Bone Mineral Density (BMD) From Baseline to 1 Year	0.048; 0.007; 0.014; 0.005; 0.019; 0.004	—
SECONDARY Rates of Metastases	—	—
SECONDARY Overall Survival	24; 22	—
SECONDARY Clinical Toxicity of ZA	36; 23	—

Eligibility Criteria

Inclusion Criteria

Postmenopausal women, Stage III or axillary node positive
Currently disease free of breast cancer and other invasive malignancies at the time of registration
No concurrent use of bisphosphonates

Exclusion Criteria

Metastatic disease

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00213980). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.